Jump to main content

TAKHZYRO (lanadelumab-flyo) is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 2 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 2 years of age.

Mobile site search icon.
Mobile navigation icon.

TAKHZYRO (lanadelumab-flyo) is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 2 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 2 years of age.

Imagine your
child's Takhzyro
Experience

It’s time to look ahead with the HAE treatment your child can take now—and later in life.

Dad of a child with HAE, teaches him how to ride a bike.

TAKHZYRO—An established partner in your child’s HAE journey

With 12+ years of experience, Takeda is committed to families living with HAE

TAKHZYRO is the #1 prescribed HAE preventive treatment.* Here are a few reasons to consider it as an option for your child:

*Based on total patients on HAE preventive treatments according to US third-party industry healthcare data.

3,250+ adolescents and adults have been prescribed TAKHZYRO since 2018

Based on third-party US specialty pharmacy data.

Established safety profile in a 52-week study of 21 children with HAE

Dosing once every 4 weeks for children less than 6 years of age or every 2 weeks for children less than 12 years of age

Dedicated support from Takeda for patients and their caregivers

See clinical study results

Learn More

Support for your child

We know that starting TAKHZYRO is a big step for your child, and we’re here to support you every step of the way. Once they’re prescribed treatment, you will receive training to ensure you know how to administer their therapy.

Do not attempt to administer TAKHZYRO to your child without first being trained by a healthcare provider. Pediatric patients (2 to less than 12 years) should not self-administer TAKHZYRO.

SEE TRAINING MATERIALS

Staying on track with your child’s treatment

You may be considering, or have already chosen, TAKHZYRO to help reduce the frequency of your child's HAE attacks. Here are some ways to support them when they get started:

  • Establish a treatment routine

    TAKHZYRO continues to work as your child takes it. So, be sure to administer it as directed without missing or skipping doses

  • Encourage your child at every dose

    Motivate your child as they continue to take TAKHZYRO, and celebrate their progress!

  • Get text reminders

    The Text Reminder Program sends dosing reminders to your mobile device. Visit TAKHZYRO.com or text "SIGNUP" to 36395 to get started*

  • Keep a Journey Journal

    Record any attacks that occur, big or small, and share that information with their doctor

    *Message and data rates may apply. Average of 3 messages per month. Text "HELP" to 36395 for more information, or text "STOP" to 36395 to end text reminders. View our Terms & Conditions at engagedrx.com/tak.

Explore more information about staying on track with TAKHZYRO.

Keep Learning

OnePath® logo.

Here to help

OnePath is a free product support program for eligible patients who have been prescribed a Takeda product.

Get Support

Talking to your child's doctor

Get a guide to have the best conversation possible.

get the guide